Structural Determinants of Imidazoacridinones Facilitating Antitumor Activity Are Crucial for Substrate Recognition by ABCG2
Authors:
- Eran E. BramEBEran E. Bram
- Yamit AdarYAYamit Adar
- Nufar MesikaNMNufar Mesika
- Michal SabiszMSMichal Sabisz
- Andrzej SkladanowskiASAndrzej Skladanowski
- Yehuda G. AssarafYAYehuda G. Assaraf
- 1 May 2009
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 75 (5) , 1149-1159
Abstract
Symadex is the lead acridine compound of a novel class of imidazoacridinones (IAs) currently undergoing phase II clinical trials for the treatment of various cancers. Recently, we have shown that Symadex is extruded by ABCG2-overexpressing lung cancer A549/K1.5 cells, thereby resulting in a marked resistance to certain IAs. To identify the IA residues essential for substrate recognition by ABCG2, we here explored the ability of ABCG2 to extrude and confer resistance to a series of 23 IAs differing at defined residue(s) surrounding their common 10-azaanthracene structure. Taking advantage of the inherent fluorescent properties of IAs, ABCG2-dependent efflux and drug resistance were determined in A549/K1.5 cells using flow cytometry in the presence or absence of fumitremorgin C, a specific ABCG2 transport inhibitor. We find that a hydroxyl group at one of the R1, R2, or R3 positions in the proximal IA ring was essential for ABCG2-mediated efflux and consequent IA resistance. Moreover, elongation of the common distal aliphatic side chain attenuated ABCG2-dependent efflux, thereby resulting in the retention of parental cell sensitivity. Hence, the current study offers novel molecular insight into the structural determinants that facilitate ABCG2-mediated drug efflux and consequent drug resistance using a unique platform of fluorescent IAs. Moreover, these results establish that the IA determinants mediating cytotoxicity are precisely those that facilitate ABCG2-dependent drug efflux and IA resistance. The possible clinical implications for the future design of novel acridines that overcome ABCG2-dependent multidrug resistance are discussed.Keywords
This publication has 41 references indexed in Scilit:
- Comparative Cytotoxicity of C-1311 in Colon CancerIn VitroandIn VivoUsing the Hollow Fiber AssayJournal of Chemotherapy, 2007
- C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cellsBiochemical Pharmacology, 2007
- Acridine and Acridone Derivatives, Anticancer Properties and Synthetic Methods: Where Are We Now?Anti-Cancer Agents in Medicinal Chemistry, 2007
- Molecular basis of antifolate resistanceCancer and Metastasis Reviews, 2007
- The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasisDrug Resistance Updates, 2006
- Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolatesCancer Chemotherapy and Pharmacology, 2006
- ABCG2 Mediates Differential Resistance to SN-38 (7-Ethyl-10-hydroxycamptothecin) and HomocamptothecinsThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Transition State Analysis of the Coupling of Drug Transport to ATP Hydrolysis by P-glycoproteinJournal of Biological Chemistry, 2003
- Mammalian ABC Transporters in Health and DiseaseAnnual Review of Biochemistry, 2002
- Competition of Hydrophobic Peptides, Cytotoxic Drugs, and Chemosensitizers on a Common P-glycoprotein Pharmacophore as Revealed by Its ATPase ActivityJournal of Biological Chemistry, 1996